
Fibrobiologics Inc (FBLG) Stock Forecast & Price Target
Fibrobiologics Inc (FBLG) Analyst Ratings
Bulls say
FibroBiologics is a promising company in the regenerative medicine and cell therapy space, with a singular focus on developing fibroblast-based therapies for a variety of chronic diseases. Their deep IP moat, platform versatility across indications, and scalable manufacturing potential set them apart from other companies in the sector and are key drivers of long-term value. Upcoming catalysts to monitor include post-split trading behavior, maintenance of NASDAQ compliance, and progress across their fibroblast-based programs.
Bears say
FibroBiologics is facing uncertainty about its future potential due to the near-term questions surrounding its Phase 1/2 trial for CYWC628 in diabetic foot ulcers, with interim data expected in 1H26. Although the company's proprietary fibroblast spheroid technology shows promise in wound healing indications, its expansion into burn injuries presents a new set of challenges, including clinical/regulatory, partnership/financial, and market share risks. Additionally, the burn care market, while significant, is highly competitive, and FibroBiologics will need to demonstrate the superiority of its approach in order to gain market share.
This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.
Fibrobiologics Inc (FBLG) Analyst Forecast & Price Prediction
Start investing in Fibrobiologics Inc (FBLG)
Order type
Buy in
Order amount
Est. shares
0 shares